Glaucoma
Diorasis Therapeutics Welcomes Dr. Dimitri Azar to Its Board of Directors
Diorasis Therapeutics; Dimitri Azar; Board of Directors; gene therapy; glaucoma; ophthalmology; biotechnology; FDA; clinical development
Kowa Secures Expanded Rights to Nicox’s Glaucoma Drug NCX 470 in Major Global Deal
Kowa; Nicox; NCX 470; glaucoma; exclusive rights; licensing agreement; Denali clinical trial; ophthalmology; royalties; milestone payments